Impact of the African American Heart Failure Trial (A-HeFT): Guideline-based Therapy in Blacks with Heart Failure 2016 National Minority Quality forum APRIL 11, 2016 Washington,D.C. Keith C. Ferdinand, MD,FACC,FAHA,FASH,FNLA Professor of Medicine Tulane Heart and Vascular Institute Tulane University School of Medicine
19
Embed
Impact of the African American Heart Faliure Trial (A-HeFT… · Impact of the African American Heart Failure Trial (A-HeFT): Guideline-based Therapy in Blacks with Heart Failure
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Impact of the African American Heart Failure Trial (A-HeFT):
Guideline-based Therapy in Blacks with Heart Failure 2016
National Minority Quality forum
APRIL 11, 2016 Washington,D.C.
Keith C. Ferdinand, MD,FACC,FAHA,FASH,FNLA
Professor of Medicine
Tulane Heart and Vascular Institute
Tulane University School of Medicine
Keith C. Ferdinand, MD
Has disclosed the following affiliations.
Any real or apparent COIs related to the presentation have been resolved.
Speaker’s Bureau-None
Grant/Research Support-Boehringer Ingleheim
Consultant
-Amgen,Sanofi,Boehringer Ingleheim, Eli Lilly
Stocks-None
Patents-None
Heart Failure Trials
Trial
Rx
Total Non-
African Americans
African Americans
African Americans
(%)
V-HeFT I + II1 ISDN/HYD, Enalapril
1419 1024 395 28
SOLVD2 Enalapril 2569 2175 394 15
US Carvedilol3 Carvedilol 1094 877 217 20
COPERNICUS4 Carvedilol 2289 2168 121 5
BEST5 Bucindolol 2708 2081 627 23
MERIT-HF6 Metoprolol 3991 3783 208 5
EPHESUS7 Eplerenone 6632 6558 74 1
Val-HeFT8 Valsartan 5010 4666 344 7
VALIANT9 Valsartan, Valsartan/Captopril
14703 14296 407 3
CHARM10 Candesartan 3023 2897 126 4
A-HeFT11 ISDN/HYD 1050 1050 100
TOTAL 44,488 40,525 3,963 7
1. Carson P et al. J Card Fail. 1999;5:178-187; 2. Hall WD. Ethn Dis. 1999;9:333-340; 3. Yancy CW et al. N Engl J Med. 2001;344:1358-1365;
4. Packer M et al. N Engl J Med. 2001;344:1651-1658; 5. BEST Investigators. N Engl J Med. 2001;344:1659-1667; 6. MERIT-HF study group. Lancet.
1999;353:2001-2007; 7. Pitt B et al. N Engl J Med. 2003;348:1309-1321; 8. Cohn JN. N Engl J Med. 2001;345:1667-1675; 9. Pfeffer MA et al. N Engl J Med.
2003;349:1893-1906; 10. Yusuf S et al. Lancet. 2003;362:777-781.
Mechanism of Action: Fixed-dose
combination ISDN/HYD
Isosorbide dinitrate (ISDN)
Large and small artery dilator
Venous dilator
Nitric oxide donor
Hydralazine HCl (HYD)
Arteriolar dilator
Fixed-dose combination ISDN/HYD
(20 mg and 37.5 mg, respectively, per tablet)
A-HeFT Trial Summary
N=1,050 AA HF , NYHA Class III-IV1,2
– 70% on ACE-I
– 17% on ARB
– Approx. 75% on β-blocker
Titration goal 2 tablets tid = 225 mg ISDN/HYD
Primary endpoint: combined score of mortality, hospitalization, and QOL
Terminated 7/19/04 for significant survival benefit in FD ISDN/HYD group
QOL, quality of life
1. Taylor AL, et al. N Engl J Med. 2004;351:2049–2057.
2. Cohn JN. Tex Heart Inst J. 2005;32(3):366–368.
A-HeFT Inclusion Criteria
Self-identified African American (black) patients
Symptomatically stable NYHA Class III-IV
On standard HF treatment
– If on β-blockers, treated for at least 3 mo prior to study entry
I I I IIa IIa IIa IIb IIb IIb III III III I I I IIa IIa IIa IIb IIb IIb III III III I I I IIa IIa IIa IIb IIb IIb III III III IIa IIa IIa IIb IIb IIb III III III
Primary HF Therapies for Blacks
Prior to the A-HeFT
Heart
Peripheral
arteries
ACE-Is, ARBs
Diuretics
β-blockers
Kidney
Modified from Jessup M, Brozena S. N Engl J Med. 2003;348:2007–2018.
Food and Drug Administration. Available at: http://www.fda.gov/bbs/topics/news/2005/new1190.html.
Standard Care Treatment post-Aheft
should include FDC of ISDN/HYD
Heart
Peripheral
arteries
ACE-Is, ARBs
Diuretics
β-blockers
Kidney
Fixed-dose
Combination of
ISDN/HYD
Modified from Jessup M, Brozena S. N Engl J Med. 2003;348:2007–2018.
Food and Drug Administration. Available at: http://www.fda.gov/bbs/topics/news/2005/new1190.html.